Persevere Therapeutics
  • Our Science
    • Pipeline
    • About Misetionamide
    • Mechanism of Action
  • About
    • About Persevere
    • Leadership
    • Board
    • Advisors
    • Contact Persevere
  • Resources
    • Publications
    • Press Releases

Let’s engage.

Innovative substance 2250, a derivative of taurultam, shows anti-neoplastic effects in malignant pancreatic carcinoma in vitro and in vivo

February 13, 2016 / 0 Minute Read

persevere therapeutics

Never. Give. Up.

A clinical-stage oncology company advancing misetionamide, a MYC-directed small molecule.

  • LinkedIn

+1.610.922.1910

Explore

  • Our Science
  • About
  • Resources

Important information

Misetionamide is an investigational agent. It has not been approved by the U.S. Food and Drug Administration or any other regulatory authority, and its safety and efficacy have not been established. Information on this site is provided for general and investor-relations purposes only and is not medical advice, an offer to sell, or a solicitation of an offer to buy any security.

Copyright © 2026 Persevere Therapeutics Inc. All rights reserved.